【导读】苹果首次在华关停直营店 中国基金报记者泰勒 大家好，简单关注下今天市场发生了什么。 苹果首次关闭中国零售店 7月29日，苹果公司将首次关闭其在中国的一家零售店，这标志着这家 iPhone制造商在这一力求重振销量的市场中出现一次显著的收缩。 苹果表示，将于8月9日关闭位于大连市中山区百年城购物中心的零售店，理由是该购物中心的环境发生变化。苹果在大中华区约有56家零售店，占其全球 530多家门店总数的逾10%。 苹果在声明中表示："我们始终致力于为所有顾客提供卓越的体验，无论是在网上，还是在大中华区50多家苹果零售店中。鉴于百年城购物中心多家零售 商相继撤离，我们决定关闭在那里经营的门店。" 此次关闭的门店是苹果在大连市的两家门店之一。另一家位于奥林匹克66购物中心的门店将继续营业。苹果表示，被关闭门店的员工将有机会调往其他地 点工作。这两家门店相距约10分钟路程。 总体而言，苹果正寻求在中国市场实现反弹。今年第二财季（截至3月29 日）苹果在中国的销售额下降2.3%至160亿美元，低于分析师预期的168 亿美 元。 另据报道，苹果将于8月16日在深圳前海万象汇开设新店，并计划在未来一年于北京和上海开设更 ...

Group 1 - Apple is set to close its first retail store in China, located in Dalian, due to changes in the shopping center environment, marking a significant contraction in its efforts to boost sales in this market [3][4] - The closure will take effect on August 9, and Apple has approximately 56 retail stores in Greater China, accounting for over 10% of its global total of more than 530 stores [3] - Despite the closure, Apple plans to open a new store in Shenzhen on August 16 and aims to establish more locations in Beijing and Shanghai over the next year [3][4] Group 2 - In the second fiscal quarter ending March 29, Apple's sales in China decreased by 2.3% to $16 billion, falling short of analysts' expectations of $16.8 billion [3] - The company is also becoming more cautious regarding lease renewals, as evidenced by the simultaneous announcement of store closures in the UK and other locations [5] - Overall, Apple's retail expansion has slowed since the pandemic, with a greater focus on online store openings in new markets like India and Saudi Arabia, as well as upgrading or relocating existing stores [4]

Group 1 - The core viewpoint of the article highlights the strong performance of innovative drugs and CXO concepts, with only one stock achieving three consecutive limit-ups, while the overall market shows a significant number of declines [1] - A total of 43 stocks hit the daily limit, with 9 stocks showing consecutive limit-ups, and a limit-up advancement rate of 20% excluding ST and delisted stocks [1] - The article notes that apart from Xizang Tourism, which achieved a limit-up, all other consecutive limit-up stocks experienced a breakdown, indicating a severe gap in consecutive limit-up stocks [1] Group 2 - The article provides specific data on stocks with consecutive limit-ups, including Xizang Tourism with a 100% advancement rate, and other stocks like Shanhua Intelligent and Nanfang Road Machinery showing lower advancement rates [2] - It mentions that the super hydropower concept continues to show strong speculative behavior, with stocks like Tuoshan Heavy Industry experiencing significant volatility [1] - The innovative drug sector is highlighted with companies like Yatai Pharmaceutical and Chenxin Pharmaceutical showing strong consecutive limit-up performances, alongside news of WuXi AppTec's better-than-expected half-year results and an upward revision of its annual revenue guidance [1]

| 代码 | 名称 | 涨幅+ | 现价 | | --- | --- | --- | --- | | 837344 | 三元基因 | +20.76% | 34.84 | | 300149 | 雪智医药 | +20.02% | 13.61 | | 300725 | 药石科技 | +18.77% | 53.10 | | 688189 | 图新制药 | +17.01% | 11.90 | | 688513 | 苑东生物 | +15.45% | 65.92 | | 300683 | 海特生物 | +15.28% | 50.61 | | 688321 | 微芯生物 | +12.85% | 38.37 | | 430047 | 诺思兰德 | +11.14% | 25.25 | | 603229 | 奥翔药业 | +10.02% | 10.54 | | 002370 | 亚太药业 | +10.02% | 6.81 | | 603367 | 辰欣药业 | +10.01% | 25.93 | | 603456 | 九洲药业 | +10.01% | 19.68 | | 601089 | 福元医药 | 49.99% | 22.90 ...

Core Viewpoint - The Hong Kong innovative drug sector is experiencing significant growth, with the largest innovative drug ETF (513120) achieving a remarkable performance, reflecting strong investor interest and favorable market conditions [1][2]. Group 1: Market Performance - On July 29, the A-share market saw a rebound, with the innovative drug sector standing out, as multiple related ETFs recorded substantial gains [1]. - The Hong Kong innovative drug ETF (513120) had a trading volume exceeding 11.6 billion yuan, closing up 4.42%, marking its fourth consecutive day of gains [1]. - As of July 29, the ETF has increased over 105% year-to-date, with its latest scale surpassing 15.1 billion yuan, making it the largest "doubling fund" among 1,234 ETFs this year [1]. Group 2: Industry Outlook - The investment value of the Hong Kong innovative drug sector remains noteworthy, especially with the upcoming policy measures from the National Healthcare Security Administration and the National Health Commission aimed at supporting high-quality development of innovative drugs [2]. - The global competitiveness of Chinese innovative drug companies is on the rise, with cross-border License-out transactions expected to exceed 60% by 2024, up from a low in 2017 [2]. - A recent collaboration between Hengrui Medicine and GSK, potentially worth 12 billion dollars, underscores the international recognition of domestic innovative drugs [2]. - By the end of 2024, China is projected to become the leading country in innovative drug research and development, with original innovations gradually emerging [2]. - The innovative drug sector is entering a phase of systematic valuation restructuring, driven by clinical data and strengthened business development expectations [2]. - The Hong Kong innovative drug ETF (513120) and its associated funds are positioned as effective tools for investors to capitalize on industry growth, benefiting from significant scale and liquidity advantages [2].

7月29日，A股三大指数继续上涨，深成指、创业板指创去年11月以来新高。 截至收盘，沪指涨0.33%报3609点，深证成指涨0.64%，创业板指涨1.86%报2406点。 全天成交1.83万亿元，较前一交易日增量632亿元，全市场超3000股下跌。 | 名称 | | 最新价 | 涨跌额 | 涨跌幅 | | --- | --- | --- | --- | --- | | 上证指数 | Shorton | 3609.71 | +11.77 | +0.33% | | 000001 | | | | | | 创业板指 | | 2406.59 | +44.00 | +1.86% | | 399006 | | | | | | 深证成指 | | 11289.41 | +71.82 | +0.64% | | 1000001 | | | | | 盘面上，CRO、创新药板块爆发，CPO、钢铁板块活跃；化学制药、F5G概念、雅下水电及半导体等板块涨幅居前。另外，保险板块走低，猪 肉、鸡肉概念走弱，银行、PEEK材料及石油等板块跌幅居前。 具体来看： CRO概念、创新药领涨大市，睿智医药、奥翔药业、亚太药业、九州药业等多股涨停。消息面 ...

Group 1 - A total of 43 stocks hit the daily limit up, with 9 stocks achieving consecutive limit ups, and 22 stocks failed to close at the limit, resulting in a limit-up rate of 66% (excluding ST and delisted stocks) [1] - Focus stocks include Tibet Tourism, which achieved a limit up for 7 consecutive days; the innovative drug concept remains strong with Apac Pharmaceutical hitting 5 limit ups in 10 days and Chenxin Pharmaceutical achieving 4 limit ups in 7 days [1] - The super hydropower concept rebounded in the afternoon, with Southern Road Machinery, Shanhe Intelligent, Tibet Tianlu, and Xining Special Steel all achieving 6 limit ups in 7 days, while Deep Water Regulation Institute reached 5 limit ups in 7 days with a 20% limit up [1]

Core Viewpoint - The pharmaceutical sector continues to strengthen, particularly in innovative drug development, with notable gains in companies like WuXi AppTec and others, reflecting a robust demand for CRO/CDMO services driven by global innovation in drug research and development [1][2][3][4][5]. Group 1: Company Performance - WuXi AppTec reported a revenue of 20.8 billion RMB for the first half of the year, representing a year-on-year increase of 20.6%, with a non-GAAP net profit of 5.58 billion RMB, up 26.5% [2]. - The TIDES business (oligonucleotides and peptides) achieved a revenue of 5.03 billion RMB, showing a remarkable growth of 141.6% year-on-year, with a backlog of orders increasing by 48.8% [2][3]. - The company has a total order backlog of 56.69 billion RMB, reflecting a growth of 37.2%, indicating strong future growth potential [2]. Group 2: Industry Trends - The global CRO/CDMO market is expected to maintain double-digit growth due to the increasing demand for innovative drug development and the rising outsourcing penetration rate [2][3]. - Revolutionary technologies such as ADC, cell and gene therapy, and mRNA vaccines are driving rapid growth in specialized fields, creating a blue ocean market for CRO/CDMO companies [3][4]. - The industry is experiencing accelerated consolidation, with leading companies benefiting from their comprehensive service capabilities and global network, enhancing their competitive advantages [4][5]. Group 3: Investment Opportunities - The BoShi CSI Pharmaceutical 50 ETF provides investors with a convenient tool to capture the growth of leading companies in the Chinese pharmaceutical industry, particularly in the CRO sector [4][5]. - The Hang Seng Medical ETF is positioned as an effective tool for investing in the Hong Kong medical sector, benefiting from policy optimizations and technological advancements [6].

Group 1 - The core viewpoint of the article highlights a shift in market structure from a "barbell strategy" to "middle assets," indicating a cyclical turning point for the technology and innovation sectors represented by the ChiNext Index and the Sci-Tech Innovation 50 Index [1] - On a macro level, the article notes that the long-term interest rate decline is slowing, coupled with policies aimed at "de-involution," which are facilitating capacity clearance and providing support for the technology growth sector [1] - The article emphasizes that new momentum industries such as AI computing power, innovative pharmaceuticals, semiconductors, and new energy are experiencing turning points in their economic conditions [1] Group 2 - The ChiNext Index reported a profit growth rate of 19% in the first quarter, showcasing a significant profitability advantage among broad market indices [1] - The current market is characterized by a "value platform, growth performance" feature, with continuous inflow of incremental funds, suggesting that the technology and innovation sectors are likely to outperform in the third quarter [1] - The Sci-Tech Innovation ETF (588360) tracks the Sci-Tech Innovation 50 Index (931643), which selects 50 representative technology innovation companies from the Sci-Tech Board and ChiNext, covering high-tech fields such as information technology, biomedicine, and new energy [1]

Group 1 - The core viewpoint highlights the strong performance and liquidity of the Science and Technology Innovation Pharmaceutical ETF managed by Harvest, which has seen significant trading activity and growth in both scale and shares [2] - As of July 28, the ETF recorded a turnover rate of 22.91% and a transaction volume of 48.1073 million yuan, indicating active market participation [2] - The ETF's net asset value increased by 54.52% over the past year, ranking it in the top 12.25% among comparable index equity funds [2] Group 2 - The top ten weighted stocks in the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index account for 50.3% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - Recent collaboration between Hengrui Medicine and GlaxoSmithKline (GSK) involves the joint development of up to 12 innovative drugs, with GSK making an initial payment of 500 million USD and potential milestone payments totaling around 12 billion USD [4] - The pharmaceutical industry is experiencing high growth, with recommendations for companies in Pharma and Biopharma/Biotech sectors as they enter a phase of performance expansion [5]